To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina - Full Text View

Purpose

This is an Argentinian, Multicentre, Observational Study to evaluate Adherence and Long Term Outcomes of Therapy in paediatric subjects using easypod™ electromechanical device for growth hormone treatment and to assess the level of adherence of subject receiving SAIZEN® via easypod™.

Condition	Intervention
Growth Disorders	Device: easypod™


Study Type:	Observational
Study Design:	Observational Model: Cohort
Official Title:	Easypod Connect: A National, Multicentre, Observational Registry to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using "Easypod™" Electromechanical Device for Growth Hormone Treatment in Argentina

Resource links provided by NLM:

MedlinePlus related topics: Growth Disorders Hormones

Drug Information available for: Somatropin

U.S. FDA Resources

Further study details as provided by Merck KGaA:

Primary Outcome Measures:

Mean percent of daily recorded adherence [ Time Frame: At least 6 months and up to 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Correlation of adherence and growth outcome after each year of SAIZEN® treatment with easypod™ [ Time Frame: At least 6 months and up to 5 years ] [ Designated as safety issue: No ]
Correlation of adherence and growth outcome (change in: height velocity (HV), height velocity-standard deviation score (HV-SDS), height, height-standard deviation score(height SDS)) after each year of SAIZEN® treatment with easypod™
Subject adherence profile based on age, gender, indication, self-injection or not, time on treatment [ Time Frame: At least 6 months and up to 5 years ] [ Designated as safety issue: No ]
Correlation of adherence with current IGF-1 status (i.e. above, below or within normal ranges) [ Time Frame: At least 6 months and up to 5 years ] [ Designated as safety issue: No ]


Enrollment:	68
Study Start Date:	March 2013
Study Completion Date:	December 2015
Primary Completion Date:	December 2015 (Final data collection date for primary outcome measure)

Intervention Details:

Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™

Other Name: Somatropin

Detailed Description:

Subjects will be enrolled in a multicenter longitudinal observational study. Parents/subjects will provide their Informed Consent/assent to upload their data for population-based analyses and, ultimately, clinical outcomes. Adherence data will be primarily derived from the easypod™ device combined with physician data entry of outcome measures. Data will be collected both retrospectively and prospectively. This will allow the establishment of adherence profiles and explore the hypothesis that patient adherence support programs improve adherence and subsequent clinical outcomes. Collected data will be also analyzed in a multinational pooled analysis of comparable national studies.

Primary Objective:

• To assess the level of adherence of subjects receiving SAIZEN® via easypod™

Secondary Objectives:

To describe the impact of adherence on clinical outcomes for subject receiving SAIZEN® via easypod™
To identify adherence subject profiling
To assess the impact of adherence on Insulin-like Growth Factor 1 (IGF1) (i.e. above, below or within normal ranges)

Eligibility


Ages Eligible for Study:	2 Years to 18 Years (Child, Adult)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using the easypod™ electromechanical device.

Criteria

Inclusion Criteria:

Administered growth hormone via the easypod™ electromechanical device according to Summary of Product Characteristic (SmPC)
Over the age of >2 years
Under <18 years of age, or over 18 without fusion of growth plates
Parent's or guardian's written informed consent, given before entering data into the observational study, with the understanding that the subject or parent/guardian may withdraw consent at any time without prejudice to future medical care. If the child is old enough to read and write, a separate assent form will be given as defined in the appropriate jurisdiction of each country

Exclusion Criteria:

Subjects taking growth hormone in whom growth plates have fused (i.e. for taking growth hormone for it's metabolic effects)
Contra-indications to SAIZEN® as defined in the SmPC
Use of an investigational drug or participation in another interventional clinical study

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01582334

Locations


Argentina
For Recruiting Locations in Argentina
please contact the Merck KGaA Communication Center, Argentina

Sponsors and Collaborators

Merck KGaA

Merck Quimica Argentina S.A.I.C

Investigators


Study Director:	Medical Director	Merck Quimica Argentina S.A.I.C

More Information


Responsible Party:	Merck KGaA
ClinicalTrials.gov Identifier:	NCT01582334 History of Changes
Other Study ID Numbers:	EMR200104-532
Study First Received:	April 19, 2012
Last Updated:	April 20, 2016
Health Authority:	Argentina: Ethics Committee

Keywords provided by Merck KGaA:


Growth disorders Saizen Easypod Growth hormone Pediatric subject

Additional relevant MeSH terms:


Growth Disorders Pathologic Processes

ClinicalTrials.gov processed this record on September 29, 2016

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina (ECOS ARG)